Related Experiment Video

Updated: Aug 9, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

[Rituximab in the treatment of B-cell non-Hodgkin lymphoma]

Zdravko Mitrović1, Igor Aurer

  • 1Zavod za hematologiju, Klinika za unutarnje bolesti, Medicinski fakultet i Klinicki bolnicki centar, Zagreb.

Lijecnicki Vjesnik
|April 28, 2006
PubMed

Rituximab, a chimeric anti-CD20 monoclonal antibody, has become a part of standard treatment of B-cell non-Hodgkin lymphoma in the last several years. Depleting CD20+ cells by various mechanisms, it is active as a single agent and particularly when combined with chemotherapy. It is effective in "in vivo" elimination of neoplastic cells from the hematopoetic stem cell transplant. Side-effects are mostly infusion related, mild to moderate, mediated by cytokine release. Because of different mechanisms of action, adding rituximab to chemotherapy does not cause additional toxicity. Combination of rituximab and chemotherapy improves response rates in indolent lymphomas and survival in aggressive lymphomas.

More Related Videos

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...